KKR has agreed to sell its controlling stake in JB Chemicals & Pharmaceuticals to Torrent Pharmaceuticals for $1.4 billion, marking a significant milestone in India's M&A landscape.
Information on the Target
JB Chemicals & Pharmaceuticals (JB Pharma) is a leading player in the pharmaceutical industry, known for its comprehensive portfolio of products that span various therapeutic sectors. With a current market capitalization of approximately $3.3 billion, the company has established a strong presence in both domestic and international markets. Despite a slight decline of 2.3% in stock value year-to-date, JB Pharma continues to innovate and expand its offerings, reflecting its commitment to enhancing healthcare solutions.
The company was founded by the Mody family and has a legacy in the pharmaceutical sector, characterized by a dedication to quality and effective healthcare solutions. KKR's acquisition of a majority stake in 2020 allowed JB Pharma to further bolster its operational capabilities and expand its reach in a competitive market.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in India
The pharmaceutical industry in India has witnessed robust growth and is projected to continue its upward trajectory, driven by a surge in domestic consumption and export opportunities. The country is one of the largest providers of generic
Similar Deals
KKR → Healthcare Global Enterprises (HCG)
2023
Eris Lifesciences → Biocon Biologics Limited - Dermatology and Nephrology Business Units
2023
Torrent Pharmaceuticals
invested in
JB Chemicals & Pharmaceuticals
in 2023
in a Buyout deal
Disclosed details
Transaction Size: $1,400M
Enterprise Value: $3,300M
Equity Value: $1,400M